Of note, since a high expression level of LAT1 is associated with poor prognosis in RCC, an LAT1-targeting anti-cancer approach has the potential to be a key therapeutic option to for malignant RCC. The gene discussed is SLC7A5; the disease is renal cell carcinoma.